Oncotarget

Research Papers:

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection

Genevra Pillinger _, Niamh V. Loughran, Rachel E. Piddock, Manar S. Shafat, Lyubov Zaitseva, Amina Abdul-Aziz, Matthew J. Lawes, Kristian M. Bowles and Stuart A. Rushworth

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:39784-39795. https://doi.org/10.18632/oncotarget.9289

Metrics: HTML 1006 views  |   ?  


Abstract

Genevra Pillinger1,*, Niamh V. Loughran1,*, Rachel E. Piddock1, Manar S. Shafat1, Lyubov Zaitseva1, Amina Abdul-Aziz1, Matthew J. Lawes2, Kristian M. Bowles1,2,**, Stuart A. Rushworth1,**

1Department of Molecular Haematology, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, United Kingdom

2Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, NR4 7UY, United Kingdom

*Denotes joint first authors

**Denotes joint senior

Correspondence to:

Kristian M. Bowles, email: k.bowles@uea.ac.uk

Stuart A. Rushworth, email: s.rushworth@uea.ac.uk

Keywords: PI3Kδ, PI3Kγ, AML, bone marrow stromal cells, duvelisib

Received: October 06, 2015    Accepted: April 16, 2016    Published: May 11, 2016

ABSTRACT

Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation. PI3K catalytic p110 subunits are divided into 4 isoforms; α,β,δ and γ. The PI3Kδ isoform is always expressed in AML cells, whereas the frequency of PI3Kγ expression is highly variable. The functions of these individual catalytic enzymes have not been fully resolved in AML, therefore using the PI3K p110δ and p110γ-targeted inhibitor IPI-145 (duvelisib) and specific p110δ and p110γ shRNA, we analysed the role of these two p110 subunits in human AML blast survival. The results show that PI3Kδ and PI3Kγ inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells. Using shRNA targeted to the individual isoforms we demonstrated that p110δ-knockdown had a more significant anti-proliferative effect on AML cells, whereas targeting p110γ-knockdown significantly inhibited AML migration. The results demonstrate that targeting both PI3Kδ and PI3Kγ to inhibit AML-BMSC interactions provides a biologic rationale for the pre-clinical evaluation of IPI-145 in AML.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9289